Avrok Biosciences’ Post

Recently, our CEO and founder Philip Ma spoke with MD+DI on the future of early cancer detection using #Multiomics. This approach brings together #Proteomics, #Genomics, #Metabolomic, #Epigenomic and #Transcriptomic data to help detect early signals of cancer in patients. Read more in the article below.

“Highly sensitive MRD tests like NeXT Personal® will open up even more opportunities to use MRD testing in a broader set of cancer types and stages,” says Dr. Richard Chen, Chief Medical Officer and EVP of R&D at Personalis in this article for Biocompare. Ultra-sensitivity is required from next-generation sequencing based minimal residual disease (MRD) tests to detect cancer recurrence early. Ultra-sensitivity has the power to deliver more trust in the negative MRD result. NeXT Personal is an ultra-sensitive and specific MRD test, which has been shown to detect early-stage lung and breast cancer recurrence months prior to disease being visible on scans. Discover more from the article: https://bit.ly/3yJdivi. #PrecisionOncology #LiquidBiopsy #NGS #MRD #ctDNA

Myriad Genetics announced that they have agreed to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD). The agreement helps solidify each company’s freedom to operate in the MRD market and broadens patient access to the benefits of MRD testing. Personalis, Inc. and Myriad Genetics are each pioneering tumor-informed, genome-scale approaches to power ultra-sensitive MRD tests, enabling earlier cancer recurrence detection and more refined therapy monitoring than alternative approaches. Read More: https://lnkd.in/d3-XnQzg #mededgemea #cancerdetection #myriad #personalis #genetictesting #oncologyresearch #cancerawareness #personalizedmedicine #HealthcareInnovation #genomics #cancerprevention #MedicalAdvancements #PrecisionMedicine

🔍 WATCH: Christos Fotis, Chief Innovation Officer at Protavio Ltd, shares critical insights into a pivotal challenge tackled by #DIOPTRA — the quest to identify protein biomarkers for early detection of #ColorectalCancer. This research is vital as it could revolutionize how we diagnose and treat this prevalent disease. Don’t miss this deep dive into the cutting-edge science shaping the future of cancer detection. 👉 Watch the interview and learn more: https://lnkd.in/egtq3QvW #HealthcareInnovation #Biomarkers #CancerResearch #HORIZONEurope

🌟 BioGenex Launches PMS2 Antibody for Enhanced Tumor Diagnosis 🌟 We're excited to introduce the PMS2 antibody, a critical tool in precise tumor diagnostics. PMS2, or Postmeiotic Segregation Increased 2, is part of a core group of DNA mismatch repair (MMR) proteins—alongside MLH1, MSH2, and MSH6—working together to detect and repair DNA replication errors, preserving genomic integrity. Gene mutations impacting the MMR system often lead to microsatellite instability (MSI), which is linked to Hereditary Non-Polyposis Colon Cancer (HNPCC) and other cancers like endometrial cancer. The resulting variations in PMS2 expression make it a valuable biomarker. The Anti-PMS2 antibody is highly recommended as part of a comprehensive panel to help differentiate gastrointestinal tract tumors, including HNPCC and associated extra-colonic cancers. BioGenex provides PMS2 antibody in both ready-to-use (RTU) and concentrated forms, within our Colorectal and Stomach Tumor Panel, suitable for both manual and automated systems. Our solutions empower pathologists and clinicians to achieve accurate, clinicopathological diagnoses, supporting drug discovery efforts and improving patient outcomes. Learn More: https://hubs.la/Q02Wgmj10 #BioGenex #CancerResearch #TumorDiagnosis #PMS2 #Pathology #PrecisionMedicine #CancerBiomarkers

We are happy to share a new blog post, “Unveiling the Power of Genomic Testing in Breast Cancer Treatment” on Learn Look Locate, exploring how genomic testing is transforming breast cancer care by analyzing the unique genetic makeup of tumors. This advanced technique provides insights beyond traditional methods, helping oncologists develop personalized treatment plans. Read the full blog: https://lnkd.in/gk84H7Gw #BreastCancer #GenomicTesting #PrecisionMedicine

I'm thrilled to share the innovative Thyroid GuidePx® test, pioneered by Dr. Oliver Bathe, which heralds a new era in thyroid cancer care with its precision in predicting recurrence risks. By examining 82 genes, this cutting-edge diagnostic tool categorizes papillary thyroid cancer into one of three molecular subtypes. This allows for personalized treatment plans that are finely tuned to each patient's genetic profile, improving efficacy and reducing unnecessary interventions 🔍👩⚕️ The Thyroid GuidePx® test is more than a medical innovation; it's a move towards a healthcare system that is personalized, predictive, and preventive. It enables clinicians to tailor follow-up and treatment strategies, thus advancing patient outcomes, enhancing quality of life, and easing the healthcare cost burden. It's great to see Dr. Bathe and his team focusing on bringing us closer to a future where treatment is as individualized as the DNA guiding it, truly embodying the promise of personalized medicine 👏🏼✅ #OliverBathe #ThyroidCancer #Oncology #PersonalizedMedicine #MedicalInnovation #HealthcareEvolution #InnovativeDiagnostics #IndividualizedTreatment #ElixirAssociates #StaffingPartner

New article! Uncover how a novel multianalyte assay has the potential to transform cancer research and treatment. 💡 In this article, Jon Ladd describes how his team integrate liquid biopsy and spatial biology data to provide deep characterization of patients’ immune response to disease. Multianalyte testing allows healthcare professionals to make and modify personalized treatment plans in real time. Read the article, https://lnkd.in/g7eASTTX #SpatialBiology #LiquidBiopsy #CancerResearch #ProstateCancer #RareCyte

🔬Immerse yourself in the dynamic world of cancer research with our latest article! Discover how biomarkers are reshaping early detection and personalized treatment strategies. 🧬 https://lnkd.in/dwzZZHUC #CancerScience #biomarkers #precisionmedicine

Comprehensive Genomic Profiling in #NSCLC Remains Underutilised! Despite the proven efficacy of targeted therapies in advanced non-small cell lung cancer (NSCLC), Comprehensive Genomic Profiling (#CGP) is still not a routine part of the diagnostic process for every newly diagnosed case. This underutilisation represents a significant gap in our healthcare system's ability to deliver precision medicine where it is most needed. The presence of actionable oncogenic driver mutations in NSCLC - ranging from more common mutations like #EGFR and #KRAS to rarer alterations such as #ALK, #NTRK, #RET, and #ROS1 - can significantly influence treatment outcomes. Advanced therapies specifically targeting these mutations have shown remarkable success in improving patient survival rates and quality of life. For example, treatments like #alectinib for ALK-positive NSCLC and #entrectinib for ROS1- and NTRK-positive tumours are changing the landscape of lung cancer care, transforming what was once a dire prognosis into manageable conditions. Given this context, it's imperative that every newly diagnosed NSCLC patient undergoes CGP before treatment decisions are made. This ensures that each patient receives the most effective therapy tailored to their genetic profile, maximising their chances of a better health outcome. As leaders in the healthcare sector, we must advocate for broader implementation of these critical diagnostic tools. It’s time to close the gap in care and embrace a future where every lung cancer patient benefits from the advances in precision medicine. Let's make CGP a standard part of NSCLC management. To discuss how LINK can support you with implementing Tempus CGP in your clinic, please contact me. #NSCLC #Oncology #PrecisionMedicine #HealthcareInnovation #Tempus #LinkMedicalSolutions Full article can be found here: https://lnkd.in/gcxwFcSg